Oncotelic Therapeutics, Inc.
OTLC
$0.056
-$0.0027-4.60%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -59.28% | -16.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -61.01% | -16.36% | |||
| Operating Income | 61.01% | 16.36% | |||
| Income Before Tax | 80.59% | -1,111.97% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 80.59% | -1,111.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -20.39% | -1.61% | |||
| Net Income | 81.82% | -1,475.07% | |||
| EBIT | 61.01% | 16.36% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 81.48% | -1,520.00% | |||
| Normalized Basic EPS | -800.00% | 66.67% | |||
| EPS Diluted | 85.00% | -1,900.00% | |||
| Normalized Diluted EPS | -800.00% | 66.67% | |||
| Average Basic Shares Outstanding | 0.00% | 1.42% | |||
| Average Diluted Shares Outstanding | 0.00% | 1.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||